Hualan Biological Unit Develops mRNA Flu Vaccine, Flags Risks
Hualan Biological said its controlling subsidiary Hualan Vaccine is developing a messenger RNA vaccine against novel influenza viruses. The project is in its advancement phase, and the company cautioned that vaccine research and development carries inherent uncertainties that could affect outcomes.
Hualan Biological said its controlling subsidiary Hualan Vaccine is conducting research and development of a novel mRNA influenza vaccine. The program is currently in its advancement phase.
The company noted that vaccine research and development involves uncertainties that may affect the project's progress and results.